Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...
The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
19h
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Bagsværd, Denmark, 5 February 2025 - Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year ...
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...
Novo Nordisk Foundation granted DKK 10 billion to benefit people and the planet in milestone year: Denmark Friday, January 31, 2025, 16:00 Hrs [IST] In 2024, on its 100th annivers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback